Finerenone provide an alternative treatment option for T2DM patients with CKD or CVD, with sustained cardiovascular benefits independent of or in combination with SGLT2i or glucagon-like peptide-1 receptor agonists (GLP-1RA). The gene discussed is GLP1R; the disease is chronic kidney disease.